Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,973,075 papers from all fields of science
Search
Sign In
Create Free Account
Factor Xa Inhibitor [EPC]
Known as:
Factor 10a Inhibitor
, Activated Factor X Inhibitor
, Activated Factor 10 Inhibitor
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Narrower (1)
Antithrombin III
Factor Xa inhibitors
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
R. Artang
,
Maren Anderson
,
P. Riley
,
J. Nielsen
Research and Practice in Thrombosis and…
2017
Corpus ID: 50786535
Essentials The value of thrombin generation assay (TGA) in monitoring direct oral anticoagulants (DOAC) is not well defined. TGA…
Expand
2016
2016
Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management
C. Dargazanli
,
N. Lonjon
,
G. Gras-Combe
European spine journal
2016
Corpus ID: 4476862
PurposeWe report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban…
Expand
2016
2016
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
Y. Miwa
,
T. Minamishima
,
Toshiaki Sato
,
K. Sakata
,
H. Yoshino
,
K. Soejima
Journal of Arrhythmia
2016
Corpus ID: 6892181
2015
2015
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
Michael A. Charters
,
N. Frisch
,
Nolan M. Wessell
,
Christopher Dobson
,
C. Les
,
C. Silverton
Journal of Arthroplasty
2015
Corpus ID: 205677766
Review
2015
Review
2015
A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After…
M. Tangelder
,
C. Nwachuku
,
+9 authors
F. Moll
Journal of Endovascular Therapy
2015
Corpus ID: 8690578
Compared with the coronary setting, knowledge about antithrombotic therapies after endovascular treatment (EVT) is inadequate in…
Expand
Highly Cited
2014
Highly Cited
2014
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial…
G. Flaker
,
R. Lopes
,
+13 authors
C. Granger
Journal of the American College of Cardiology
2014
Corpus ID: 205559142
Highly Cited
2014
Highly Cited
2014
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
T. Fuji
,
Cj Wang
,
S. Fujita
,
Y. Kawai
,
T. Kimura
,
S. Tachibana
Journal of Arthroplasty
2014
Corpus ID: 205676988
Highly Cited
2013
Highly Cited
2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
C. Gibson
,
A. Chakrabarti
,
+10 authors
E. Braunwald
Journal of the American College of Cardiology
2013
Corpus ID: 26086920
Review
2013
Review
2013
The Cost‐Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low‐Molecular‐Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery
M. Mahmoudi
,
D. Sobieraj
Pharmacotherapy
2013
Corpus ID: 25522752
Major orthopedic surgery is associated with a high risk of venous thromboembolism (VTE). Anticoagulants are recommended to…
Expand
2013
2013
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
T. Kadokura
,
M. Kashiwa
,
+5 authors
Hartmut Onkels
Biopharmaceutics & drug disposition
2013
Corpus ID: 205459387
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE